ARCC-4 is an androgen receptor PROTAC based on an enzalutamide-derived AR ligand and a von Hippel-Lindau-recruiting ligand. The AR-binding portion recognizes the receptor ligand-binding domain, while the VHL ligand recruits the VHL ubiquitin-ligase complex through the opposite end of the molecule. This design allows ARCC-4 to act as a degrader rather than merely a receptor antagonist, because linker-mediated ternary-complex formation brings AR into a ubiquitination-competent environment. Mechanistically, ARCC-4 promotes AR ubiquitination and proteasomal depletion, including degradation of receptor variants or mutants relevant to antiandrogen research models as described in public summaries. It is useful for investigating AR protein dependence, resistance-associated receptor biology, nuclear receptor degrader selectivity, VHL-based PROTAC design, and comparative studies of transcriptional outcomes after receptor blockade versus receptor removal.
Structure of 1973403-00-7
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: ARCC-4 selectively targets androgen receptor and clinically relevant AR mutant variants.
Binding site: Its enzalutamide-derived ligand binds the androgen receptor ligand-binding domain.
Mechanism of action: ARCC-4 is a VHL-recruiting androgen receptor PROTAC based on an enzalutamide-derived AR antagonist linked to a VHL E3 ligase ligand. The compound induces proximity between AR and the VHL ubiquitin ligase complex, resulting in AR ubiquitination and proteasome-dependent degradation. This mechanism enables direct removal of AR protein, including mutant forms, rather than competitive suppression of ligand-dependent transcription alone. ARCC-4 is useful for studying AR degradation kinetics, mutant receptor susceptibility, transcriptional pathway shutdown, and experimental differences between receptor antagonism and targeted receptor depletion.
Applications• PROTAC-Mediated Kinase Degradation: ARCC-4 is utilized in research to selectively degrade kinases, offering a novel approach to study kinase signaling pathways. This facilitates the investigation of cellular processes and the identification of potential therapeutic targets by modulating kinase activity through targeted protein degradation.
• Targeted Degradation in Cancer Research: Researchers employ ARCC-4 to explore the degradation of oncogenic proteins, providing a powerful tool to dissect cancer cell biology. By precisely removing specific proteins, scientists can better understand tumorigenesis and identify vulnerabilities within cancer cells.
• PROTAC-Based Drug Resistance Studies: ARCC-4 aids in the study of drug resistance mechanisms by degrading proteins involved in resistance pathways. This application allows researchers to pinpoint critical nodes in resistance networks and develop strategies to overcome therapeutic challenges.
• Cellular Pathway Analysis via PROTACs: ARCC-4 is instrumental in mapping cellular pathways by degrading key regulatory proteins. This targeted approach helps elucidate complex biological networks and the roles of specific proteins in maintaining cellular homeostasis.
| ConcentrationVolumeMass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 0.98 mL | 4.88 mL | 9.76 mL |
| 5 mM | 0.2 mL | 0.98 mL | 1.95 mL |
| 10 mM | 0.1 mL | 0.49 mL | 0.98 mL |
| 50 mM | 0.02 mL | 0.1 mL | 0.2 mL |
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.